BridgeBio Pharma, Inc. (MUN:2CL)

Market Cap	12.80B
Revenue (ttm)	301.53M
Net Income (ttm)	-679.38M
Shares Out	n/a
EPS (ttm)	-3.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7
Average Volume	282
Open	61.58
Previous Close	54.20
Day's Range	61.58 - 62.18
52-Week Range	24.59 - 62.18
Beta	n/a
RSI	75.47
Earnings Date	Feb 20, 2026

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 730
• Stock Exchange: Munich Stock Exchange
• Ticker Symbol: 2CL

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Financial numbers in USD